International legal practice Osborne Clarke has advised Delphi Genetics, a plasmid DNA (pDNA) cell and gene therapy contract development and manufacturing organization (CDMO) based in Gosselies, Belgium, on its acquisition, by Catalent through an auction process in coordination with the US-based investment bank, Achelous Partners. The sale was completed with a valuation of the company at 55 million USD.
The team was led by Partner Hadrien Chef and included Laurent De Pauw (Associate, Corporate), Tonya Aelbrecht (Senior Associate, Corporate), Karen Calvo Vleugels (Junior Associate, Corporate), Benjamin Docquir (Partner, IT/IP), Chloé Ponsart (Associate, IT/IP), Vinciane Rysselinck (Senior Counsel, Employment) and Olivier Lambillon, (Counsel, Tax).
This transactions demonstrates the ongoing full spectrum legal support provided by Osborne Clarke to life science & healthcare companies operating in Belgium’s growing biotech, medtech and pharma sector. Osborne Clarke combines sector knowledge and a global reach to support clients at all stag-es of business growth and the team has the extensive knowledge to guide clients as they navigate the complexities of R&D processes, fundraising and acquisitions, data protection, workforce strate-gies, and regulatory compliance.
About Delphi Genetics
Founded in 2001 as a spin off from the Université libre de Bruxelles (ULB), Delphi Genetics is a lead-ing bioproduction CDMO with capabilities in handling the entire plasmid DNA development and CGMP manufacturing process. Its operations are headquartered at a 17,000-square-foot (1,600-square-meter) facility, adjacent to Catalent’s current cell therapy facilities. Delphi has built a reputation for its ‘one-stop-shop’ capabilities that include process development, pilot production, plasmid design and production, strain screening and stability, and which span from preclinical to Phase 3 applications, using fully single-use technology.
Catalent is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. Catalent’s acquisition of Delphi’s pDNA technology and production capabilities marks a significant milestone for Catalent Cell & Gene Therapy. With these new services, Catalent’s fully integrated cell and gene offering will allow customers to de-risk and optimize their programs along the entire development pipeline.